Nilotinib 300mg BID as frontline treatment of CML:Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response

Michael E O'Dwyer, Ronan Swords, Arnon Nagler, Mary Frances McMullin, Philipp D le Coutre, Stephen E Langabeer, Alberto Alvarez-Iglesias, Hongxin Fan, Richard C Woodman, Francis J Giles, Eibhlin Conneally

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Sixty patients with early chronic phase CML (ECPCML) received Nilotinib on a phase II study which included a comparison of the Xpert BCR-ABL Monitor™ PCR system with standardized (IS) BCR-ABL1 real-time quantitative PCR (RQ-PCR). 88% patients achieved MMR with 45% achieving MR4.5. At 3 months BCR-ABL1/ABL1 IS >1% and <10% was associated with a lower likelihood of subsequent MR4.5 compared to patients with lower levels (p = 0.018). No significant difference was observed between methodologies in identifying MMR. Nilotinib induces high molecular response rates in ECPCML and the Xpert BCR-ABL Monitor™ system merits further investigation in this setting.
Original languageEnglish
Pages (from-to)310-315
JournalLeukemia research
Volume38
Issue number3
Early online date01 Dec 2013
DOIs
Publication statusPublished - Mar 2014

Bibliographical note

Copyright © 2013 Elsevier Ltd. All rights reserved.

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Nilotinib 300mg BID as frontline treatment of CML:Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response'. Together they form a unique fingerprint.

  • Cite this

    O'Dwyer, M. E., Swords, R., Nagler, A., McMullin, M. F., le Coutre, P. D., Langabeer, S. E., Alvarez-Iglesias, A., Fan, H., Woodman, R. C., Giles, F. J., & Conneally, E. (2014). Nilotinib 300mg BID as frontline treatment of CML:Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. Leukemia research, 38(3), 310-315. https://doi.org/10.1016/j.leukres.2013.11.016